Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
TORRENT PHARMACEUTICALS LTD. - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Download announcement < Back
24 Jan 2023
This is with respect to our earlier communication on September 28, 2022 regarding the USFDA inspection at our manufacturing facility at Indrad, Gujarat and issuance of Form 483 by USFDA with 3 observations. We now wish to inform that the Company has received a communication from the USFDA determining the inspection classification as &apos;Official Action Indicated&apos; (OAI). This inspection classification will not have impact on existing supplies or revenues from this facility. Torrent Pharma continues to cooperate with the USFDA and will undertake all necessary remedial steps to resolve these issues to the satisfaction of the regulator. Torrent Pharma remains committed to being cGMP compliant quality standards across all its facilities. Please take the information on record.
View all announcements for TORRENT PHARMACEUTICALS LTD. Source: BSE India